Barry Weiner just Sold 11,000 shares of Enzo Biochem, Inc. (ENZ), be careful if you are long!; Sphera Funds Management LTD Lowered Immunomedics (IMMU) Holding

As reported in a legal report which was filled with the Washington-based SEC on 19/01/2018, Barry Weiner, President – CFO – Treasurer – PAO of Enzo Biochem Inc and a well informed person, made a sale of 11,000 shares of the company and paid for them about $85,250 US Dollars based on an average stock price per share of $7.8. Barry Weiner currently owns 1.29 million shares which are equivalent to roughly 2.75% of the New York-based company’s market cap.

Sphera Funds Management Ltd decreased Immunomedics Inc (IMMU) stake by 18.18% reported in 2017Q3 SEC filing. Sphera Funds Management Ltd sold 100,000 shares as Immunomedics Inc (IMMU)’s stock rose 37.64%. The Sphera Funds Management Ltd holds 450,000 shares with $6.29M value, down from 550,000 last quarter. Immunomedics Inc now has $2.57 billion valuation. The stock increased 0.95% or $0.15 during the last trading session, reaching $15.99. About 1.50 million shares traded. Immunomedics, Inc. (NASDAQ:IMMU) has risen 76.26% since January 21, 2017 and is uptrending. It has outperformed by 59.56% the S&P500.

The stock increased 2.18% or $0.17 during the last trading session, reaching $7.96. About 147,953 shares traded. Enzo Biochem, Inc. (NYSE:ENZ) has risen 44.32% since January 21, 2017 and is uptrending. It has outperformed by 27.62% the S&P500.

Analysts await Enzo Biochem, Inc. (NYSE:ENZ) to report earnings on March, 12. They expect $-0.01 earnings per share, up 50.00% or $0.01 from last year’s $-0.02 per share. After $-0.01 actual earnings per share reported by Enzo Biochem, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Enzo Biochem, Inc., an integrated diagnostic bioscience company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company has market cap of $373.53 million. The firm operates in three divisions: Clinical Labs, Life Sciences, and Therapeutics. It currently has negative earnings. The Clinical Labs segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication levels, and search for an otherwise undiagnosed condition.

Since October 25, 2017, it had 0 insider buys, and 3 sales for $1.51 million activity. RABBANI ELAZAR sold $730,526 worth of stock or 72,401 shares. WEINER BARRY W sold $547,214 worth of stock. O’Brien James Michael had sold 22,866 shares worth $235,062 on Friday, October 27.

Investors sentiment decreased to 1.24 in Q3 2017. Its down 0.35, from 1.59 in 2017Q2. It is negative, as 18 investors sold Enzo Biochem, Inc. shares while 28 reduced holdings. 23 funds opened positions while 34 raised stakes. 25.84 million shares or 2.45% more from 25.22 million shares in 2017Q2 were reported. Jefferies Gp Limited Company has 15,300 shares. 1.00M were reported by Acadian Asset Management. Wellington Grp Inc Llp reported 0.01% of its portfolio in Enzo Biochem, Inc. (NYSE:ENZ). 95,476 are held by Kempner Capital Mngmt Inc. Susquehanna Intll Group Inc Llp has invested 0% of its portfolio in Enzo Biochem, Inc. (NYSE:ENZ). Bankshares Of Ny Mellon reported 0% stake. Caprock Group invested in 0.02% or 11,270 shares. Parametric Portfolio Associate Lc holds 0% of its portfolio in Enzo Biochem, Inc. (NYSE:ENZ) for 43,456 shares. Millennium Management Ltd Liability Corporation holds 0% or 188,199 shares in its portfolio. Mckinley Cap Mngmt Limited Liability Com Delaware reported 0.16% of its portfolio in Enzo Biochem, Inc. (NYSE:ENZ). Barclays Public Limited Com has 18,157 shares for 0% of their portfolio. Sei accumulated 8,507 shares. Tiaa Cref Inv Management Limited Liability Company has 735,555 shares for 0.01% of their portfolio. Renaissance Tech Ltd accumulated 2.14M shares or 0.03% of the stock. 2,753 are held by Advisory Services Net Limited Liability Com.

Investors sentiment increased to 1.65 in Q3 2017. Its up 0.24, from 1.41 in 2017Q2. It increased, as 16 investors sold IMMU shares while 36 reduced holdings. 38 funds opened positions while 48 raised stakes. 111.69 million shares or 33.14% more from 83.89 million shares in 2017Q2 were reported. Wellington Grp Limited Liability Partnership holds 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU) for 151,347 shares. 203,083 are held by Citigroup. Fred Alger Mgmt holds 14,000 shares. Knott David M holds 65,483 shares or 0.39% of its portfolio. Nea Ltd reported 1.36% stake. Panagora Asset Incorporated owns 649,601 shares. Legal And General Gp Public Ltd Liability Corp holds 0% in Immunomedics, Inc. (NASDAQ:IMMU) or 26,991 shares. 2.86M are held by Ecor1. Price T Rowe Associates Md reported 6.38 million shares or 0.02% of all its holdings. California State Teachers Retirement Sys accumulated 163,599 shares. Credit Suisse Ag stated it has 129,313 shares. 135,000 are owned by Atika Capital Management Limited Liability Com. State Bank Of Ny Mellon Corp holds 0% or 681,419 shares in its portfolio. Moreover, Wolverine Asset Management Ltd Liability Corp has 0.06% invested in Immunomedics, Inc. (NASDAQ:IMMU). Metropolitan Life Insurance New York invested in 0.01% or 71,552 shares.

Since August 21, 2017, it had 0 insider purchases, and 6 sales for $2.10 million activity. 40,000 shares valued at $369,426 were sold by GOLDENBERG CYNTHIA L on Monday, August 21. GOLDENBERG DAVID M had sold 40,000 shares worth $428,946.

Analysts await Immunomedics, Inc. (NASDAQ:IMMU) to report earnings on February, 8. They expect $-0.10 EPS, up 37.50% or $0.06 from last year’s $-0.16 per share. After $-0.16 actual EPS reported by Immunomedics, Inc. for the previous quarter, Wall Street now forecasts -37.50% EPS growth.

Among 3 analysts covering Immunomedics (NASDAQ:IMMU), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Immunomedics has $16 highest and $1.50 lowest target. $15.50’s average target is -3.06% below currents $15.99 stock price. Immunomedics had 15 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was maintained by Cowen & Co on Monday, July 24 with “Buy”. On Wednesday, December 6 the stock rating was maintained by Cowen & Co with “Buy”. The firm earned “Buy” rating on Wednesday, August 16 by Cowen & Co. Jefferies maintained the stock with “Buy” rating in Monday, October 9 report. The firm has “Buy” rating by Jefferies given on Tuesday, September 19. The stock of Immunomedics, Inc. (NASDAQ:IMMU) earned “Buy” rating by Jefferies on Thursday, October 6. The firm has “Buy” rating by Jefferies given on Friday, June 9. Wells Fargo downgraded the shares of IMMU in report on Tuesday, June 21 to “Market Perform” rating. The firm has “Buy” rating given on Wednesday, December 6 by Jefferies. Jefferies maintained the shares of IMMU in report on Thursday, August 17 with “Buy” rating.

Sphera Funds Management Ltd increased Summit Therapeutics Plc stake by 70,000 shares to 212,018 valued at $2.65 million in 2017Q3. It also upped Alphabet Inc stake by 1,421 shares and now owns 5,767 shares. Minerva Neurosciences Inc (NASDAQ:NERV) was raised too.